Literature DB >> 24242026

Association between local interleukin-6 levels and slow flow/microvascular dysfunction.

Fangming Guo1, Mei Dong, Faxin Ren, Chuanhuan Zhang, Jianping Li, Zhigang Tao, Jun Yang, Guangping Li.   

Abstract

We aimed to investigate the association between local interleukin-6 (IL-6) levels at the infarct-related artery and the risk of slow flow/microvascular dysfunction after PCI in ST-elevation acute myocardial infarction (AMI) patients treated by successful primary PCI. 56 eligible ST-elevation AMI patients (34 male/22 female, mean age: 63.5 ± 10.3 years), undergoing successful primary PCI, were included in the current study. Blood samples were obtained from the extraction catheter placed distal to the lesion before PCI. Plasma IL-6 levels were determined by immunoassay method. Slow flow/microvascular dysfunction was observed in 21 patients (37.5%). Using multiple logistic regression analysis, local IL-6 levels (OR 1.592, CI 1.135-2.268; P = 0.007) were found to be a significant risk factor of slow flow/microvascular dysfunction together with diabetes mellitus (OR = 8.065, CI 1.244-52.632; P = 0.029) and thrombus score (OR = 12.500, CI 1.100-142.857; P = 0.042). Receiver operating characteristic (ROC) curve analysis revealed that local IL-6 (ROC area 0.824, OR 1.704, CI 1.274-2.281, P < 0.001; optimal threshold ≥11.3 pg/ml) had a predictive value of slow flow/microvascular dysfunction with sensitivity of 73% and specificity of 71%. Our study indicated that inflammatory response as presented by local IL-6 levels was associated with slow flow/microvascular dysfunction in patients with ST-elevation AMI after successful primary PCI.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24242026     DOI: 10.1007/s11239-013-0974-0

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  33 in total

1.  Time course of transcardiac interleukin-6 release after coronary stenting for stable angina.

Authors:  J M Kefer; L M Galanti; C E Hanet
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

2.  Aortic pressures, stiffness and left ventricular function in coronary slow flow phenomenon.

Authors:  Halil Tanriverdi; Harun Evrengul; I Dogu Kilic; Ozgur Taskoylu; Güllü Dogan; Seref Alpsoy
Journal:  Cardiology       Date:  2010-08-26       Impact factor: 1.869

Review 3.  Deleterious effects of oxygen radicals in ischemia/reperfusion. Resolved and unresolved issues.

Authors:  R A Kloner; K Przyklenk; P Whittaker
Journal:  Circulation       Date:  1989-11       Impact factor: 29.690

4.  C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction.

Authors:  Stein Ørn; Cord Manhenke; Thor Ueland; Jan K Damås; Tom Eirik Mollnes; Thor Edvardsen; Pål Aukrust; Kenneth Dickstein
Journal:  Eur Heart J       Date:  2009-03-19       Impact factor: 29.983

5.  Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina.

Authors:  G Liuzzo; A Buffon; L M Biasucci; J R Gallimore; G Caligiuri; A Vitelli; S Altamura; G Ciliberto; A G Rebuzzi; F Crea; M B Pepys; A Maseri
Journal:  Circulation       Date:  1998-12-01       Impact factor: 29.690

6.  Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease.

Authors:  S B Larsen; E L Grove; S D Kristensen; A-M Hvas
Journal:  Thromb Haemost       Date:  2013-02-14       Impact factor: 5.249

7.  Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog.

Authors:  R L Engler; G W Schmid-Schönbein; R S Pavelec
Journal:  Am J Pathol       Date:  1983-04       Impact factor: 4.307

8.  Elevated levels of interleukin-6 in unstable angina.

Authors:  L M Biasucci; A Vitelli; G Liuzzo; S Altamura; G Caligiuri; C Monaco; A G Rebuzzi; G Ciliberto; A Maseri
Journal:  Circulation       Date:  1996-09-01       Impact factor: 29.690

Review 9.  Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory.

Authors:  Shereif H Rezkalla; Robert A Kloner
Journal:  Catheter Cardiovasc Interv       Date:  2008-12-01       Impact factor: 2.692

10.  Interleukin-6 induces Gr-1+CD11b+ myeloid cells to suppress CD8+ T cell-mediated liver injury in mice.

Authors:  Liang Cheng; Jun Wang; Xiaozhu Li; Qiao Xing; Peishuang Du; Lishan Su; Shengdian Wang
Journal:  PLoS One       Date:  2011-03-04       Impact factor: 3.240

View more
  4 in total

1.  Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: Results from the Multi-Ethnic Study of Atherosclerosis.

Authors:  Tracey G Simon; Maria Esther Perez Trejo; Robyn McClelland; Ryan Bradley; Michael J Blaha; Irfan Zeb; Kathleen E Corey; Matthew J Budoff; Raymond T Chung
Journal:  Int J Cardiol       Date:  2018-05-15       Impact factor: 4.164

Review 2.  From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection.

Authors:  Paul M Ridker
Journal:  Circ Res       Date:  2016-01-08       Impact factor: 17.367

3.  Interleukin 6 trans-signalling and the risk of future cardiovascular events in men and women.

Authors:  Yasmin Miri; Karin Leander; Per Eriksson; Bruna Gigante; Louise Ziegler
Journal:  Open Heart       Date:  2021-10

4.  Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction.

Authors:  Lara S F Konijnenberg; Peter Damman; Dirk J Duncker; Robert A Kloner; Robin Nijveldt; Robert-Jan M van Geuns; Colin Berry; Niels P Riksen; Javier Escaned; Niels van Royen
Journal:  Cardiovasc Res       Date:  2020-03-01       Impact factor: 10.787

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.